Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:LXRX NASDAQ:PTGX NASDAQ:REPH OTCMKTS:ULUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.43-4.7%$6.59$3.93▼$7.54$346.13M1.67646,639 shs1.18 million shsLXRXLexicon Pharmaceuticals$1.15+3.6%$1.12$0.28▼$2.18$403.37M1.261.65 million shs1.68 million shsPTGXProtagonist Therapeutics$58.86-1.4%$55.70$33.31▼$61.89$3.71B2.22869,797 shs685,841 shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-4.74%-6.68%-1.98%+4.38%+15.03%LXRXLexicon Pharmaceuticals+3.60%+5.50%+3.60%+71.26%-31.95%PTGXProtagonist Therapeutics-1.37%-2.76%+3.77%+4.42%+31.41%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$6.43-4.7%$6.59$3.93▼$7.54$346.13M1.67646,639 shs1.18 million shsLXRXLexicon Pharmaceuticals$1.15+3.6%$1.12$0.28▼$2.18$403.37M1.261.65 million shs1.68 million shsPTGXProtagonist Therapeutics$58.86-1.4%$55.70$33.31▼$61.89$3.71B2.22869,797 shs685,841 shsREPHRecro Pharma$1.73$1.38▼$3.79$117.93M1.08126,298 shs141,800 shsULURULURU$0.00$0.10▼$0.79$5.35M-3.136,691 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-4.74%-6.68%-1.98%+4.38%+15.03%LXRXLexicon Pharmaceuticals+3.60%+5.50%+3.60%+71.26%-31.95%PTGXProtagonist Therapeutics-1.37%-2.76%+3.77%+4.42%+31.41%REPHRecro Pharma0.00%0.00%0.00%0.00%0.00%ULURULURU0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.50203.27% UpsideLXRXLexicon Pharmaceuticals 2.50Moderate Buy$3.23180.43% UpsidePTGXProtagonist Therapeutics 3.09Buy$67.7315.07% UpsideREPHRecro Pharma 0.00N/AN/AN/AULURULURU 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LXRX, REPH, ABEO, PTGX, and ULUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025PTGXProtagonist TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/12/2025PTGXProtagonist TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$73.009/2/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/18/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/15/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$19.00 ➝ $20.008/7/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform8/7/2025LXRXLexicon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.20 ➝ $1.908/7/2025PTGXProtagonist TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$67.00 ➝ $69.007/14/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.006/24/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$72.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$400K824.31N/AN/A$1.01 per share6.37LXRXLexicon Pharmaceuticals$31.08M13.45N/AN/A$0.40 per share2.88PTGXProtagonist Therapeutics$209.18M17.51$4.46 per share13.21$11.33 per share5.20REPHRecro Pharma$75.36M0.00N/AN/A$0.90 per share0.00ULURULURUN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.709.19N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7084.09N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)REPHRecro Pharma-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/AULURULURUN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest LXRX, REPH, ABEO, PTGX, and ULUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million8/6/2025Q2 2025PTGXProtagonist Therapeutics-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AREPHRecro PharmaN/AN/AN/AN/AN/AULURULURUN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65LXRXLexicon Pharmaceuticals0.434.164.16PTGXProtagonist TherapeuticsN/A16.9716.97REPHRecro Pharma2.273.242.74ULURULURUN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%LXRXLexicon Pharmaceuticals74.70%PTGXProtagonist Therapeutics98.63%REPHRecro Pharma62.34%ULURULURUN/AInsider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%LXRXLexicon Pharmaceuticals13.90%PTGXProtagonist Therapeutics4.90%REPHRecro Pharma14.20%ULURULURU1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million47.74 millionOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionablePTGXProtagonist Therapeutics12062.21 million59.16 millionOptionableREPHRecro Pharma18556.42 million48.41 millionOptionableULURULURU230.57 million30.24 millionNot OptionableLXRX, REPH, ABEO, PTGX, and ULUR HeadlinesRecent News About These CompaniesJourney Beyond inch closer to$300m Uluru deal with Voyages Indigenous Tourism AustraliaSeptember 12 at 9:34 AM | ntnews.com.auNJetstar drops massive $120 spring sale to popular tourist destinationSeptember 11 at 5:02 AM | skynews.com.auSUluru’s only resort set to land new private equity-backed ownerSeptember 11 at 5:02 AM | afr.comJetstar launches NT sale to grow Top End and Red Centre tourismSeptember 10 at 11:56 PM | travelweekly.com.auTJetstar drops insane $129 sale to hotspotSeptember 10 at 6:56 PM | news.com.auNJetstar Unveils Big NT Sale to Boost TourismSeptember 10 at 6:56 PM | miragenews.comMUluru, Fuji and the Great Wall: The most amazing sights to look out for mid-flightSeptember 6, 2025 | telegraph.co.ukVANLIFE in the Red Centre, Part 2 - Outback Australia | Uluru, Kata Tjuta and Kings Canyon | Ep. 14September 6, 2025 | msn.comInfluencers Spark Outrage Over Uluru Photo ControversySeptember 3, 2025 | msn.comSix influencers went on a trip to Uluru and totally missed the pointSeptember 1, 2025 | metro.co.ukM‘Deeply educational’: Influencers defend Uluru trip after backlash over ‘insensitivity’August 31, 2025 | dailytelegraph.com.auDUluru Dialogue pushing to ‘reignite’ Indigenous constitutional recognitionAugust 31, 2025 | skynews.com.auSUluru Dialogue vow to renew recognition fightAugust 29, 2025 | theaustralian.com.auYouTubers Find Out Uluru's Rules Are No JokeAugust 27, 2025 | msn.comOnboard Qantas’ Brand New A220 Over the Australian OutbackAugust 26, 2025 | msn.com‘Not an attractive destination’: Couple films Uluru, commits ’20 fineable offences’August 26, 2025 | msn.comTourists shocked when ordered to delete photos of oft-visited area — and they could have faced a hefty fine: ‘We weren’t aware about that’August 25, 2025 | msn.com‘20 fineable offences’: Aussie couple’s shock email three months after Uluru tripAugust 25, 2025 | news.com.auNTravel vloggers given ’20 fines’ after filming during visit to historic world site – how you can avoid the same mistakeAugust 25, 2025 | thesun.co.ukUluru tourists ordered to delete photos of sacred sites - and they could have faced a hefty fine: ‘We weren’t aware about that’August 25, 2025 | skynews.com.auSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, REPH, ABEO, PTGX, and ULUR Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$6.43 -0.32 (-4.74%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$6.62 +0.19 (+2.88%) As of 09/12/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Lexicon Pharmaceuticals NASDAQ:LXRX$1.15 +0.04 (+3.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.14 0.00 (-0.43%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Protagonist Therapeutics NASDAQ:PTGX$58.86 -0.82 (-1.37%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$58.86 0.00 (0.00%) As of 09/12/2025 06:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Recro Pharma NASDAQ:REPHRecro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.ULURU OTCMKTS:ULURULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
